Oracea phase 3 clinical trials show 'highly significant' results


Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.